Allspring Global Investments
SYRE icon

Allspring Global Investments’s Spyre Therapeutics SYRE Stock Holding History

Allspring Global Investments’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$541K Buy
+6,090
New +$444K ﹤0.01% 1432
2022
Q2 		– Sell
-46
Closed -$2K – 2923
2022
Q1 		$2K Sell
46
-7
-13% -$588 ﹤0.01% 3001
2021
Q4 		$6K Buy
+53
New +$8.37K ﹤0.01% 2928

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Allspring Global Investments's SYRE Position: Q2 2026 in Review

Allspring Global Investments opened a new position in Spyre Therapeutics (SYRE) in Q2 2026: 6,090 shares worth $541K. The stake represents ﹤0.01% of the portfolio and ranks #1432 among its holdings. This is a return to the name: Allspring Global Investments previously reported a position in SYRE as recently as Q1 2022.

Allspring Global Investments first reported a position in SYRE in Q4 2021 and has held it in 3 quarters since. 266 funds tracked by Wall St. Rank hold SYRE as of Q2 2026.

  • Allspring Global Investments held 6,090 shares of Spyre Therapeutics worth $541K as of Q2 2026.
  • Spyre Therapeutics was a new Allspring Global Investments position in Q2 2026.
  • Spyre Therapeutics made up ﹤0.01% of Allspring Global Investments's portfolio in Q2 2026, its #1432 holding.
  • Allspring Global Investments first reported a position in Spyre Therapeutics in Q4 2021 and has held it in 3 quarters since.
  • 266 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q2 2026.

Based on Allspring Global Investments's 13F filing for Q2 2026, filed 13 Aug 2026.